49 scheduled presentations will explore several types of cancer, as well as the next frontier of health equity NEW BRUNSWICK, N.J., May 23, 2024 /PRNewswire/ -- Clinicians and scientists from...

We are advised by LiFE in the Air that journalists and other readers should disregard the news release, LiFE IN THE AIR ANNOUNCES PARTNERSHIP WITH INFLIGHTDUBLIN, issued 21-May-2024 over PR Newswire.

nab-Sirolimus demonstrated significantly greater intratumoral drug concentration, stronger inhibition of mTOR targets and greater antitumor activity compared to IV and oral mTOR inhibitors in a...

-- Updated Phase 1 dose escalation data show that BLU-222 in combination with ribociclib and fulvestrant was well-tolerated at clinically active dose levels with no dose-limiting toxicities -- --...

Oral presentation of final five-year results from the registrational Phase 2 trial in R/R mIDH1 AML patients reinforces REZLIDHIA® (olutasidenib) efficacy in heavily pretreated patients,...